#ACR25 Abstr#801 Post-hoc analysis of Phase 2 RCT showed longer duration on Ianalumab (IAN) is beneficial. More #SLE pts achieved LLDAS or DORIS remission and GC taper in IAN in blinded 28-wk phase + open label IAN for the next 24-week group vs PBO-Open Label IAN @RheumNow https://t.co/I1Ugfj3BBl